Eli Lilly investors look for insight into Foundayo launch data, Reuters says

Following Q1 results, Eli Lilly (LLY) investors will be searching for insight into the launch of weight-loss pill Foundayo, Chris Prentice and Mariam Sunny of Reuters reports. The pill, an offering meant to rival Novo Nordisk’s (NVO) Wegovy pill, was launched in early April, so several additional weeks of data is needed to determine Foundayo’s early sales trajectory. Initial data, however, has prompted some analysts to say Foundayo’s launch is lagging behind Wegovy.